Syngeneic central nervous system transplantation of genetically transduced mature, adult astrocytes.
Advances in the development of highly infectious, replication-deficient recombinant retroviruses provide an efficient means of stable transfer of gene expression. Coupled with ex vivo transduction, surrogate cell populations can be readily implanted into the brain, thus serving as vehicles for delivering selected gene products into the central nervous system (CNS). Here we report that rat astrocytes can be routinely and safely isolated from brain tissue of a living donor by use of short-term gelatin sponge implants. The mature, nontransformed astrocytes were easily expanded, maintained in long-term tissue cultures and were efficiently transduced with an amphotropic retrovirus harboring a heterologous, fused transgene. In vitro retroviral infection rendered the nontransformed cells essentially 100% viable after exposure. The level of efficiency of infection (30-50% effective genome integration of provirus and expression of transgene in target cell populations) and minimal cell toxicity obviated the need to harvest large numbers of target cells. Cultured transduced astrocytes were resilient and exhibited select peptide expression for up to 1 year. Subsequently, transduced astrocytes were used in a series of experiments in which cells were transplanted intracerebrally in syngeneic animals. Post-implantation, astrocytes seeded locally and either insinuated into the surrounding parenchyma in situ or exhibited a variable degree of migration, depending on the anatomic source of astrocytes and the targeted brain implantation site. Transduced astrocytes remained viable in excess of 8 months post-transplantation and exhibited sustained transgenic peptide expression of green fluorescent protein/neomycin phosphotransferase in vivo. The sequential isolation and culture of nontransformed, mature, adult astrocytes and recombinant retrovirus-mediated transduction in vitro followed by brain reimplantation represents a safe and effective means for transferring genetic expression to the CNS. This study lays the foundation for exploring the utility of using a human autologous transplantation system as a potential gene delivery approach to treat neurological disorders. Prepared and utilized in this manner, autologous astrocytes may serve as a vehicle to deliver gene therapy to the CNS.
Selkirk
S M
SM
Laboratory of Neuroimmunology and Neurovirology, Department of Neurology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Greenberg
S J
SJ
Plunkett
R J
RJ
Barone
T A
TA
Lis
A
A
Spence
P O
PO
D000818:Animals; D001253:Astrocytes / Q000637:transplantation*; D001921:Brain; D018929:Cell Culture Techniques; D002469:Cell Separation; D002493:Central Nervous System Diseases / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage; D049452:Green Fluorescent Proteins; D019868:Kanamycin Kinase / Q000235:genetics*; D008164:Luminescent Proteins / Q000235:genetics; D023421:Models, Animal; D051381:Rats; D011916:Rats, Inbred F344; D012190:Retroviridae; D014161:Transduction, Genetic / Q000379:methods; D014182:Transplantation, Autologous
D008164:Luminescent Proteins; D049452:Green Fluorescent Proteins; D019868:Kanamycin Kinase